Bristol-Myers Squibb
275 S Bryn Mawr Ave, F18,
Bryn Mawr
PA
19010
United States
Tel: 269366-0681
193 articles about Bristol-Myers Squibb
-
Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production
4/26/2023
Bristol Myers Squibb (NYSE: BMY) today announced expansion of its global cell therapy manufacturing network to enable in-house viral vector production through a U.S.-based manufacturing facility and its operations in Libertyville, Illinois, following the company’s execution of an agreement with Novartis.
-
Foundation Medicine and Bristol Myers Squibb Expand Partnership to Focus on Companion Diagnostic Development
4/11/2023
Expanded collaboration aimed at developing FoundationOne CDx as a companion diagnostic for Bristol Myers Squibb’s investigational tyrosine kinase inhibitor, repotrectinib.
-
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
3/28/2023
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis.
-
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab)
3/23/2023
BridgeBio Pharma, Inc. today announced that the first patient with non-small cell lung cancer (NSCLC) has been dosed in its Phase 1/2 clinical trial of BBP-398, an investigational SHP2 inhibitor, with Bristol Myers Squibb’s OPDIVO® (nivolumab) in advanced solid tumors with KRAS mutations (NCT05375084)
-
CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs
3/20/2023
CHARM Therapeutics today announced a strategic discovery collaboration with Bristol Myers Squibb (NYSE: BMY) for the identification and optimisation of compounds against Bristol Myers Squibb selected targets.
-
Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion & Diversity Goals and Health Equity Commitments
3/15/2023
Bristol Myers Squibb (NYSE: BMY) today announced meaningful progress toward its global inclusion & diversity goals and health equity commitments, meeting and exceeding some goals ahead of schedule.
-
Bristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023
3/9/2023
Bristol Myers Squibb (NYSE: BMY) will announce results for the first quarter of 2023 on Thursday, April 27, 2023.
-
Bristol Myers Squibb Receives European Commission Approval of Reblozyl® (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
3/3/2023
Bristol Myers Squibb Receives European Commission Approval of Reblozyl ® (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia.
-
The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor
3/2/2023
Bristol Myers Squibb (NYSE: BMY) in collaboration with Janssen Pharmaceuticals, Inc. today announced the launch of the Phase 3 Librexia program studying milvexian, an investigational oral factor XIa (FXIa) inhibitor (antithrombotic).
-
Bristol Myers Squibb to Present Data Supporting its Cardiovascular Portfolio at the American College of Cardiology Annual Scientific Session Together With World Congress of Cardiology
2/27/2023
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research supporting the company’s cardiovascular franchise at the American College of Cardiology (ACC) Annual Scientific Session & Expo together with the World Congress of Cardiology (WCC), taking place in-person and virtually March 4-6, 2023.
-
Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference
2/3/2023
Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at the Guggenheim Healthcare Talks 2023 Oncology Conference on Thursday, February 9, 2023.
-
Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318
2/2/2023
Exscientia plc (Nasdaq: EXAI) today announced that EXS4318 ('4318) a compound precision designed by Exscientia and in-licensed by Bristol Myers Squibb in August 2021, has entered Phase 1 clinical trials in the United States.
-
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
2/2/2023
Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter and full year of 2022, which reflect robust growth of the in-line and new product portfolios, driven by strong commercial execution and continued progress of the company's pipeline.
-
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta Thalassemia
1/27/2023
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl ® (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta Thalassemia.
-
Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
1/27/2023
Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis,
-
Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi® (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
1/26/2023
Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi ® (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.
-
Dragonfly Therapeutics Announces Sixth Dragonfly TriNKET Opt-in by Bristol Myers Squibb
1/6/2023
Dragonfly Therapeutics, Inc. today announced that Bristol Myers Squibb exercised its option to enter into an exclusive license for a sixth TriNKET Immunotherapy drug candidate, that will bring the total drug candidates licensed by Bristol Myers Squibb to seven including Dragonfly's novel IL12 cytokine DF6002/BMS-986415.
-
Bristol Myers Squibb to Present at J.P. Morgan’s 41st Annual Healthcare Conference
1/3/2023
Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 41st Annual Healthcare Conference on Monday, January 9, 2023.
-
Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, New York
1/3/2023
Bristol Myers Squibb (NYSE: BMY ) has completed the previously announced sale of its manufacturing facility in Syracuse, New York to LOTTE BIOLOGICS.
-
Envisagenics Announces Research Collaboration with Bristol Myers Squibb
11/29/2022
Envisagenics today announced a research collaboration agreement with Bristol Myers Squibb (NYSE: BMY).